SLC32A1 and Alzheimer disease: Although, in a model of AD of intracerebroventricular administration of soluble Aβ1–42 which leads to memory impairment and loss of nerve terminals whithin 2 weeks the density of GABAergic terminals (VGAT positive) was not affected in the hippocampus of C57BL6 mice [83].